Qamzova Injection
NDC Package 82972-001-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Qamzova (meloxicam) injection is meloxicam is used to treat arthritis. This formulation utilizes a injection delivery system. Marketed by Nanjing Delova Biotech Co., Ltd., this product is identified by NDC 82972-001 and is authorized under FDA application NDA217593.

Identification & Billing

NDC Package Code
82972-001-30
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE
Product Code
82972-001
11-Digit Billing Format
82972000130
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Qamzova
Non-Proprietary Name
Meloxicam
Substance Name
Meloxicam
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
MELOXICAM 30 mg/mL
Pharmacologic Class
Usage Information
Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.

Regulatory & Marketing

Labeler Name
Nanjing Delova Biotech Co., Ltd.
Product Type
Human Prescription Drug
FDA Application #
NDA217593
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-15-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82972-001-30 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose of Qamzova, a human prescription drug labeled by Nanjing Delova Biotech Co., Ltd.. This injection is formulated for intravenous use and contains meloxicam as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nanjing Delova Biotech Co., Ltd. on October 15, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.

How is this Nanjing Delova Biotech Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82972000130. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82972-001-30
11-Digit CMS (5-4-2)
82972-0001-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.